2023 has been a year of changing tides for Blue Water Biotech, and the last few months appear to be producing some particularly rough seas. With a freshly minted CEO, the biotech is redefining its mission to focus solely on oncology, a move that includes dropping six FDA-approved drugs and its wide-ranging vaccine portfolio.
Bispecific developer LAVA Therapeutics is cutting a trial for a candidate targeting hematological malignancies after reviewing the current competitive landscape, choosing instead to double down on its solid tumor program.
Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine
Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights
Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development
Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates
Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors
Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco